The country’s most valued pharmaceutical company has outperformed the market by surging 37% so far in current calendar year 2013 compared to 4% rise in benchmark Sensex. Sun Pharma said that its proposal to hive off its domestic formulations business in favour of Sun Pharma Laboratories Ltd (SPLL) has been approved by the High Courts of Gujarat and Mumbai.
Meanwhile, the company will announce results for the fourth quarter and the financial year ending March 31, 2013 on May 28, 2013. According to analyst at Angel Broking, the pharma major is likely to clock 20.2% year-on-year (yoy) growth on the sales front, led by both exports and domestic sales. The net profit is likely to grow 21.5% yoy during the quarter.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
